Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
Recruiting in Palo Alto (17 mi)
+5 other locations
Age: 18+
Sex: Male
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Kangpu Biopharmaceuticals, Ltd.
No Placebo Group
Trial Summary
What is the purpose of this trial?
This trial tests a new drug called KPG-121, taken regularly, in adult subjects. The study aims to determine the safest dose and how well it works.
Research Team
YW
Yao Wang
Principal Investigator
Kangpu Biopharmaceuticals, Ltd.
Eligibility Criteria
Inclusion Criteria
Able to swallow and retain orally administered medication;
Male aged 18 years and older (adult, older adult) at the time consent is obtained;
Histologically or cytologically confirmed diagnosis of prostate carcinoma;
See 9 more
Exclusion Criteria
You have a severe medical condition affecting your brain or nervous system.
You have received chemotherapy, radiation or experimental immunotherapy within the last 4 weeks. Limited radiation to control bone pain is allowed.
You cannot take certain medications during the study, including experimental drugs, anti-cancer treatments, and certain herbs or supplements.
See 26 more
Treatment Details
Interventions
- Abiraterone (Hormone Therapy)
- Apalutamide (Hormone Therapy)
- Enzalutamide (Hormone Therapy)
- KPG-121 (Other)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: KPG-121Experimental Treatment1 Intervention
Safety and Antitumor Activity of KPG-121 capsules at different dose level for 21 days
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
North Shore Hematology Oncology AssociatesPort Jefferson Station, NY
Clinical Trial SiteLas Vegas, NV
Clinical Trial SitePort Jefferson Station, NY
Comprehensive Cancer Centers of NevadaLas Vegas, NV
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Kangpu Biopharmaceuticals, Ltd.
Lead Sponsor
Trials
4
Patients Recruited
150+